Edition:
United Kingdom

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

6.85USD
15 Dec 2017
Change (% chg)

$0.34 (+5.22%)
Prev Close
$6.51
Open
$6.45
Day's High
$6.85
Day's Low
$6.45
Volume
718,989
Avg. Vol
41,641
52-wk High
$7.85
52-wk Low
$4.40

Chart for

About

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)

Overall

Beta: 0.25
Market Cap(Mil.): ¥24,203.37
Shares Outstanding(Mil.): 35.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

07 Dec 2017

BRIEF-Medicinova announces collaboration

* Medicinova announces collaboration with the U.S. Department Of Veterans Affairs and Oregon Health & Science University to evaluate MN-166 (ibudilast) in methamphetamine use disorder

09 Nov 2017

BRIEF-Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)

* Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability

26 Oct 2017

BRIEF-Medicinova Inc files for potential mixed ‍​shelf of up to $200 million

* Medicinova Inc files for potential mixed ‍​shelf of up to $200 million - SEC filing Source text: [http://bit.ly/2fgDO2R] Further company coverage:

22 Sep 2017

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence

19 Sep 2017

Earnings vs. Estimates